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Ckmiaz+zm is B cbbmAaiva!ive o?diltiaam, a banmthinz- 
epine-type calcium channel blockw. In animal tiiea 
(1). clantiazam salectively dilates cotmluy and cerebml 
arteries end is a more m&et caroma~ vesedilater than 
diltiazem. Clentiaaa is &re Gpophilicihan dihiaam end 
has a lunger halfMe (40 to 13 h) in halthy- &n(can f.2). 
IIdsntrv~decrcasesmMal~aurcinhypertcmiw 
ratp. and dogs with little C&F: on heart ratt and myocardlsl 
conuactlllty 0, These cherectaislb may provo K&III in 
the treatment of stable anginq ecnbral iachtmia and bypcr- 
:;asion. 
This report describes ihe results of the lmt lwge rdiicacy 
and safety study dclentiazem in piwds With stable @on. 
The objective of the trial was to evnluate the dose-responlc 
relation dclentinzem when given twice daily at doses of20 
IO I20 qfday. 
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pressure NJ.5 mm tfg; 7) sinus brndycnrdia 40 bcaWmin 
while Wng no antianginal mcdiuuion; 8) other condirbas 
mat signihcantly limit exercise cepachy; 9) sigrdkanl renal, 
hqadc, endocrine or ncwobgic discasq IO) known allergy 
or senskivity to calcium channel blockers; and II) any 
wmdilion lrnorvn (0 intwfwe with the ystmbucslinll ab- 
swptianafdnyr.TbcstudywrssppmvedbytbcE&ics 
Committee at en& ofthe 22 sites. Written intbrmed wnsntt 
was ebtuinal tium all petients b&e enrallmenl. 
A botpl of US pntients were rendmnized, but 56 ff tkm 
were excluded from the efticacy enrdysis beceuse of prcme- 
wrewilhdrawal(n=n)or~wpnoeol~(n= 
Z9). Ibus, 193 ptienur am included in the 66icacy mudysir 
rmd 255 in tk safety amdysir. 
w dwl6n. The design of this multkentw, random- 
ized. doublsblind, plsaboattmllcd. pwallel de&g study 
w*lmsErAt” 96s 
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Fip?e I. smdy design. 
I J . 
1 3 4 
is somomrixcd in Fii 1. At tiu fust visit. a treadmill 
exercise te5t teas obtained for faatiliariultioa if the patient 
had not had such a Lest within the previous 2 week;. Al1 
medications known tu tiect amriea tiuencv ur ST see- 
tnmtts, cxcupt &lingual nitro&zerin. ~rehiscontinu~ 
& a minimum of 5 half-lives. At visit 2. patiems bcgaa I 
week of?h&bhd placebo therapy and returned after rbe 
we&. At both visits 2 sod 3. oatiomr ociformcd another . _ 
treadmig~ to&: to ouafifv tbr taodomizatioa. muicots 
IWE tt~~rod lo I) c&l& zt!l mir of the Bruce &d. 
2) develop moderate aoghta or 21 nun (0.1 mW uf ST 
.qment depressinn Bunt hasclinc within 3 to 7 min of the 
start of the lust, 3) complete the test within IO min, havhtg 
dcv&pcd both angina and ST dcpressiuu, aad 4) exhibit 
<I596 w&ability ia exercise dmatbm behvcca visits Zaad 3. 
Eligibk patients were roodnmiti tc rcceivc placebo or 
dmtiaaem (2ll. 40. %I or 120 at&lay) in a doobie-blind 
~.~theacxt7dpys.tbcriludy~waadtrated 
in a Uepwise tttattwfrom ZOtngMay (orequiwlettl plae&l 
w the full be. Doses were inere~ al sdny inkrvals 
wldtou any Interim visits until the as@~al dose was 
twcbed. Tltaraftn. lhey rc.&ved plaecbo or dentittzem at 
the same daily dotx during rhc next 7 o IO days. Modiitioa 
wus admlnistared as tablets twice daily with momiag and 
ovoniag d&g. Compliaocc was &tamiaed bv tablet cooot 
aml was navm <SO% for any patient. 
e Tits ptimary. pnduCned dSunry end g&t 
wg8 exercise duretiun. Secondary efficacy end pnints were 
rime~unset0fafnaaidtitnecoImmufSfdupi&uudepmsion. 
AU exmuisc lusts were psrfurmed with the Btucc protocol. 
Patioutsrcfmit&fmmsumkiugacatiagforZhbt~the 
test. Tests were coodoctod in the mominn. 12 + I h alter the 
cvoniryQwffsndthtn4+lhafkrthe~~~d~,at 
visits 3 &as&m) and 5. Ao ckc~~~r&cgmt& (ECG) lead 
ums wntiuy rwwded duriw the teal nd lFcovcry. 
CuBhloudomssure.heattrateaadaIl-LeadiXGwere 
mded II ihe emI h egch stage, at the vnse~ of at@na. at 
the cuumt of I mm of ST domcssioa and at the cod of .-----. .. 
excruisu, Dtuiq the bas&m cxucisc lest 4 h after ths dose 
@aoeboatvisit3. tbo):rimaryroasoa foratoppin.gexcrciae 
. . . 
weeb (meao z gD). Forty goLot of the pati&ts had had a 
pmvioos myocardial h&t&a. 13% had h+ tonmary by- _. . . . . . 
was art& h I63 patients. otarked ST depressioa in 4. pass mugcry and 11% hi had comrw~ WWlaslY. Anal- 
fatiie in 16 and dyspnea in 16. The roasnns for stoppiag 
exerrisc were siutibu ia Iae live wentmenl groups. Ho&g- 
tal or downsloping ST dcprossion was nteastmrd at tJ.tB 3 
atIrr the J point and was compared with the NcagllrclllcIlt in 
Ihe hawline traciuf. Tltc depth of ST daprcasion was always 
reponed from tbc grst leod tbut showed =I mm d ST 
dcprcssioa nurittg the test at visit 2. 
In o diary. patients noted rho number aad severity of 
aagioa qiscdcs. their oitK&cerht Wimump& aad side 
effects. Diug safety was assusred by means of the garicaf 
diaries. vital siis. rest BCGs and laboratury nests. Blued 
j-ample3 for clemiazem plasma wmxntratlon wre cvllcctcd 
at the ead of the pfacebu run-in (c%ttrol), the cud of the 
titration weok (amtpWcc check) and the nd of the treat- 
mcatpcriodatI2aod4haftcrdosiug.Accottolb&oratory 
aoafyxcd d aampks osiog o bigb prcrsom liqoii chromatog- 
rpphy assay. ~8 dcacrii pmvkmsfy (2). 
Stat&al yubda. An analysis of variance (ANOVA) 




IWM valuea ror sire aad tmatmatt e&ck Exercire dumtioa 
was~imudlortinett~~t~~w~ti~~ 
tbeoosctof I mmdSTdqessionwhtathscoadgoiats 
did not occur. A nmbability d 55% ~8s cc&&red hulii 
alive uf a signiS&t diiumtcg. All tnpmted p values tuc 
two-trtilcd: values mu expressed as mean value 2 SE unlws 
otherwise ¶flled. 
FatId feahm. The mean age of the 199 patients in- 
cluded in the ehiracy analysis was 61 f 8 years fnuan + 
SD:: them were 24 wuntun and I75 men. The duration of 
aa& was 2 I year in 74%. 41% welt in CMMiau Cardip 
vascular Society ltutctional claw 1 and 55% wcm in class II; 
at basclbm study. ooticots ~oortod 3.5 * 6 aoaiaoi atta&sI 
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ysl6 of variance reveeied no rigni6cent dllrenees &morrg 
the five Sroups in terms ofage, gender, race. cetdhic histoty. 
srtgial pressure and heart rate. I)sta from all sites were 
pwlcd because uo treatment by site interaction wus found. 
ExraWetuarsmtltsfrab&1,Fl&2).-fIlcexercisetext 
resultsf~oathethrecetiicacycndpol~at)hafkrdoaingare 
listed in Table 1. The improvement from buse!fnc values for 
cxetnirsduretionwes slgnlReentlygreater wltboientieuerat 
dosss of 49 m&ey (63 = 11 s). 80 tnt&hty (93 + IO s) end 
t20 mglday (76 + II 11 thau with placebo (34 -f 10 I). Thees 
differences ere depicted in Ff8ure 2. lmptwemeut trJm 
badine values for time tc onset of at&a and rime to I mm 
of ST depression was also si@ficautly ~rcater with clen- 
tiazem WI and I29 mg&y) then with plu~ebo. The 2&n@ 
day dose did not ai@?ceutfy itnptnve any of the thres 
exercise end points. Althou& the 8O.&dny dose wes 
superior to 46 m&ny, no edditionel benefit wes seen with 
I2tl tu8Msy. 
At 4 h efter dosing, the number of patients for whom 
%lgil% Was the primary reason for slopping exerclss de- 
CreWed from 33 ttl 23 hl the placebo .@~p, 27 to I9 in the 
Wm@day fzuup. 35 to 24 in the #mJdaygWp, 35 to 26 in 
the SCM#lay ~prmp and 33 to 12 in the 12o_n@day Sroup 
compared with the bnseline test at visit 3. 
At 12 h sfter dosing, n si@ficent improvement in all three 
e&aCy end points tnletive to baseline values wee seen only 
with clentiarcm at adose of 129 r&day (bottom petrels. pCe. 
2). Mae duration, but not time to the onset of au8ine or 
fTf dour&on was sinnit%antlv belter with the 8Dmeldnv 
done &mqmred with -rIacCbo.- A hiildy s&niti~unl linear 
trend existed among the five treatmen groups for eU three 
etllcacy end points at both 4 end 12 h efter dosing. 
group whore anxine did not RCYT during the treatment test et 
4 h efter dos@ was 3.7,s. 14 end 18. turpedively. in the 
ptawbo und 2iL 4% W uud IBinSAhty &a 8Knps. 
Lihewise, .scvc.n fmtlents did nat rlevclop I mm uf ST 
Wression duriug the baselhm test. Trcutmcnt at 4 II after 
QailyelimiWed STdeptussionin 1,6,8, IZand 1Spatlents 
per nsuecrive urouo. 
each of the Sve goups. includiq the plscebe group. Aml- 
ysisofvurlnnccsbnwedaliiurdoselrendumongthehve 
lrcnbncnt erouus lo = 0.04Sk howevur. the dilference be- 
tween ctci&-iid snd’placcboaemed patiemr m 
not stutialcally si@%ant (p - 0.22). The mean nitmgly~- 
ain wnsurnptfon per week m busellnc testily was upproxi- 
mutely 0110 t&let perweek in erh ~mup end did not cheese 
si@cnr~Uy with lrentment. 
If- W 3). AI nsr. At 4 h ntter dosiqg, 
clentisxem at doses of 80 and 129 tn@dey significantly 
reduced heart raw. systolic turd diusbtlic sricriul pressure 
and rate-uressurc modtmt camoered with vubtes with rile. 
C&I. At -12 h after do&S, the ‘oaly reduction thut r&i& 
stetlsticaf si@6Ceocc @ c O.ool, wes for heart Rue with 
clentinxem at doses of 80 n&fey (fnuu 76 to 72 f 2 
ImettJmin) nnd 120 mg/dey (ftiun 80 to 73 * 2 beetsAnin). 
EmI Qf *loge I (&iwaximal crercisr). At 4 b elter 
de& n dosedependent reduction in heart rate WW+ ob 
served ff%le 3). The rate-fnussure produet was dsreosed 
sifarfScantly more from bascliue w&h clsntiaxem (Sll and 
129 m&lxy) tbun with placebo. fiJ 12 h after dosi~, thcrc 
were no si&icaa differences behveen phteebo end clen- 
tiazem at any dose level for systolic or dinmdii Mood 
pmsuue. However, clentieuem (40, 80 end 126 n@dey) 
decmsd the rabsprear: pmduct stiaolly mom than 
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did placebo at end of s@e 1 relative to baseline values. This plrap ckntkan m (I@. 3), A linear trend 
decrease was mainly due lo a reduction in heart rate. WM absmed between dcntiazcm dosx and plasma comxn- 
At peak rxerrlse. At 4 h after clentiazem (120 mg/dayl, nation at 4 and II h atter dosing. No @n&ant mm&ion 
benrt rate, diistolic blond pressure and ratepressure pmd- was noted betwcrll exercise dutaliin and plrrmii clcntiwcm 
uct wcm &creased flable 31. Tbc darcase in ratc-acssure comccmrsrion~r=0.116rad~195a~4sndI2h.~saeetive- 
pmdwt as also c&td a&y by a decrease in b&t rate. IY). 
At 12 h after dosing, only heart rate decreased r~nificamtly Adversz events. Clmtiazem sat&4 wan evaluated in a 
in patients treated witb lUl- and lZl%mglday doses. total of 255 patients. One or more treatment-related rnlvcrx 
HcKl nr (bulshl01 
~ofabgel 
EL?*2 al*2 7-3572 75 k 2 x+2 I2 * 2 ia* xl*29 II?3 73?T 
11o+2 109~2 I%?2 101*3 ml*2 95*2t 104*2 matzt %9+3 95*2! 
AtD?akexwdpc nllt1 139+3 134t3 134*4 12s*3 124+3* 134+3 131+2 137 * 3 124t2t 
sysuiic bkd prcslm mm Hgl 
Pm DO+3 I31 + 3 129*3 r24t2 12lI+2 12622 lJl+2 f25+2* 132+2 124+?l 
Eadofslyl 14923 14623 Mo*3 Ill+3 l&t3 M3*3 W/*3 143k3 l53*3 l43?T 
AlpeakcxcrclrC 167r3 163*4 1mt4 162*5 %2+4 I9224 161t3 169t4t 199t4 laai4 
Mw&~MIwc~~wc(~~~ 
IlBl a*1 7922 7921 78+2 ilot 1621 81 f I 7621' tot1 75+ I' 
BlddSlagel 9352 92+2 mt2 %+I mzl 79 t 2‘ 8251 ItI a*1 76+2t 
Afpmkrlrrclsc %i2 64*2 k2r2 91 +2 Wf2 II 2 2 u+2 1252 85*1 79=2t 
Rawp-essLut pIdWlxl0"~~ 
llrll 10.7~0.4 IaSta3 LOta 9.2205 9,7t13 9.00*03 IalrO.3 ldtO37 la7f0.4 9J*O.3t 
Bnddlbgl 16.JtO~ lalr a6 IL7 to.6 IL3tO"f 119*a3 13**ocl 15.4*tl.4 13.4(+OA 16.7*oA 13.7 +ut 
AtpuPexercir 23.1 I 0.7 22.9 *as 21.5 f a9 21.9 5 ia aaa f a9 203 * 0.7 219 t 0.7 72.2 * 0.7 232 f od 28.9 *a9t 
*P<O~tp<LOl~cb~~~M~~c~~~s-v~~3~wnu~~~A~~K~~eK~~u~~~*~ 
evcotswarerepottedby29%ofpatients69of D%e&iql 
clentiazcm and 27% of plants (14 ofS2) raceiving placebo. 
3v&i!, x!~-e events cccurrcd more frcqttanfly after 
clentiazem at IM m&day (29%~ than with lower doses (16% 
17% and 26% with 3,40 and 80 m#day) or phxebo (20%). 
The m~tEommonadveraecventWOdaa~ni~,repo~~ in 
7.9% of pticnts receivia~ clemiazem aad I 1.5% of patients 
receiving placebo. 
Pirst~atrioventiul~ (AV)bbckdevdqxdafter 
mmbmization only in clentiazam-treated patients, while 
they wera receiving 20 muday (n = I), 40 &day (n - 31, 
80 &day (II = 4) and 110 tag/day (II - 5l durbtghe titmtion 
or treatmentperi~s.,?nepatientcngcdcDced Wenckebacb 
type sea&degree AV block after receivirg 40 mg!day of 
deatiaam and three ptkot8 developed juncrioael rhythm 
wilb doses of40,80 aad I20 m&lay, respectively. None of 
these unubwtion disturbances caused symptoms. Rve oftbe 
six pa&au with 6rstdegraa AV blockbefore tnadomiitioa 
raeciwdclenti~mandinnoneolth~wa9marc~~ 
blockdetcctcddutirlgtJWmem. 
Twelve pent9 (47%), indudial ci#ht rcdvhg den- 
tiazem,wamwitbdrawoftomthcstudybecauseofadvarae 
eveats. Two of the cl@ clmt~r&ed patienrs were 
hxxpitalizcd, oae fur unstable aagbm aad one for myoeardii 
infarction. The other six ck&zetlFtreatcd patients were 
witbdrawofmmtbe8ttdybecrm3eofincr&tgaagbm 
Metttiazam dose 20 ma/d& tiearee AV block 
(40 @day), ioffuenza~(46’&/day), n&iple -aa 
(20 a@day) and fatigua in two patients (40 and 120 m&lay. 
reapectivdy). 
Adoae-dependeotinereaseiothePRinervalwasob- 
served with tmatmeot. With 120 a@d~y of claatiazan, the 
PRln~rvalin~rsed~O.IQloO.l~rPt4b~&si~ 
andfrom0.168to0.175sat IZh.TbeQRSintewalwasaot 
tieetcd by eicntlazem. The drug had no deleterious effects product was thus signiticantly reduced and tbc reduction 
on taboratory test reatdts.. Analysis of adverse events by persisted during submaximal exarctan. At pak exercise, tba 
subgroup (age, gender runt clinical features) did not raveal ~re-prar~urr product was similar to that at the control test 
any diEel7mces. for alt clentiazem doses except I2tl mg/day. Thus, den- 
t&m appeared to improva aaarcisa uurfmmanee by de- 
DlSCllSSiOIt 
This abort-term study suggests that clentiazsm given 
twice daily can improve the exercise teat performance of 
godents with stable angina signiftcatttly better than ean 
placebo. At 4 h after dosing, improvement was seen with 
doses of 80 and 120 n@day. The &mg/day dose also 
increasad examisa duration signilicantly but only the 80 and 
120-mg/day doses significantly poatponad the onset of angina 
and ST deprnsaion. The 20-nut/day dose had no et&t. At 
12 h atIer dosing. the &I. and 12(1_mg!day doses still had a 
banoticial e&t on exercise performance. 
The numbar of angina1 attacks mtd nmount of nitmglyc- 
minconaumedduring thetreatment phasesofthe study were 
low; the dacraase with ckntiasam did not attain statistical 
aignkIeanes. 
Cnmp&ao wltb gawtous atudlm. This is the first study 
to examine tba affact of clentiazem in patients with stable 
anginn. However, the utttiangittal efficacy of diltiazem. a 
dntgwith a sir&t chemical structure, has been documented 
in tttmty previous studias. As seen with clentiasetu iu this 
study, inetumental doses ofdiltiazcm from 120 to 36h mg/dny 
have restdtad in improved exarcisa tolerance (6-S). AC 
thou& diltiazem has baen shown to reduce nitmglycerin 
constt@ou and to docn9u9e tba rmmbar ofanginal attack9 
in studies when !hese syttg~~s occwred hnqttently in the 
placebo periods (9). the redttctiott did not attain stntisticsl 
s&dReaocc itt most studies (10-12) when anghm occurred 
less ftoqoatttly. similarly, the reductions with clentiasem in 
this study were not 9iguiRcant. 
The rnt@u of impmvammt io exmciae capacity with 
diltbmam in prnvious studies was quite broad and thus the 
s¶icncy of olentiazem atul diltiavem cannot be aecmately 
compatetl. In any case. impmvemfnts in lhe ru9ulis Of 
col:vontional exercise testing may underestimate the benefit 
of an mdianninal drue. In a txevious trial (12). diltiazem 
redueod the-ntetlino &sbar ba isehemie episodes during 
daily lii by threefdd but increased exercise time to the 
onset diaehetnia by onty 15%. 
The plasma half-life of diltiazcm is 4 to S h (13) nnd 
ntttinnghtal efficacy, although waning, can stiil be demo+ 
strated at 6 or 8 b athsr acute doailyl (14.15). Sustained= 
rakare preparations extend the antiungitmt effect of the drug 
to ~12 h (16,17). making hasible a twice-daily- dosiag 
achcdule. The results uf this trial demonsttate that cian- 
tiusam, becauaa of its hatf-life of IO to 13 h. maintains its 
Cmcncy at I2 h aftur doring. It ean thus be given twiee daily 
without rasorting to a sustained-release formulation. 
&&a&mu af rthn. At rest, clentiazem induced small 
but signbimmt doaodependant decremants in haart rata and 
sli@tly redueud systolii arterial pressure. The rate-prassure 
craaz+ myocardii o&en consumption at each l&d cd 
exercise. Similar hcmodynamic &acts have been reported 
with diltiazem ~C4.ll.17). The possibUy that part of the 
beneficial affect ofckntiazam on cxereisc pdurmawe may 
bc tide lo an increase in myccardial bleed supply throngb 
coronary vaaodiiation cannot be r&d out. 
correlatton With gsnsma emmWr&n. No a@iEemtt 
correlation was noted between exercise end points amI 
p!aama clentiazem concentration: howevar, the pkxmta con- 
centration increased with increasing dose lcvcls (Fig. 3). 
This lack of cormlmiou may be duo to a hilt immpntient 
variability in bwh clinical respmwa and drug plasma eoncen- 
tration. It could alao tx explained by tba tow cortelatii 
obtuincd within each dose group; patiants with the higheat 
plasma concentration did not necessarily ahow the pernest 
response. These results stu&sst that the clinical tqunse ttt 
clemiazem may be related to dtug tissue content tather than 
to plasma concemration. Suppottkg this hyyhesis. Du- 
mont et al. (18) demonattated that the effect of ckntiazemon 
the heart rate of anesthetized dogs WK&M better with the 
mpcardiil content of the drug than with its plasma concan- 
tration. The correlation between plasma diitiazem concen- 
tration and exareisa pnkmance in previous studii has 
been either not statistically aigniticant (lS,l6) or weak (19). 
Admrm aUmta. In a phase 1 study in healthy male 
volunteers (15). single daily &us delentiuzem up to 120 oy 
itxreased the PR itttetvnl in a dosedepctulent fttshion. Less 
prolongation of the PR iMoNal wns observed in om stndy 
(I9 vs. 59 ms for tire IBm#day doaa) and our rosult.9 ware 
obtained unds steady stata conditions hsstmtd of aftor a 
single dose. Naverthalesa. the davalopmant of AV t&k 
appears to be the faetot that will limit the dose ofelentiasem 
that can be recommended for clinical use. First-degree AV 
bkxk occurred in 5 of’lhe SO patients toceiviag the 17otngI 
day dose of clenliazem. Ruther studies are needed to 
evaluate clentiazem in combination with other drugs and in a 
broader range of patients before the importance of &ds 
limitation can be aceurateIy asacsaed. The ability of elm- 
dazem to slow cooduction through the AV node may prove 
to ba thempeutienlly useful; diltinmm has been shown to 
terminate (20) and pravent (21) supravWticular taehycnrdis 
and to control the ventriculet fate ia patients with attial 
tibrillalion (22.33). 
None of the other adverse effects men in this study were 
r@ilieantly more common with cleutistcm than with pla- 
cebo. Clentiazam did not cause any abnoneatitiea in the 
routine Iaboratory tests that were monitored. 
Conclusiana. This large, double-blind, placebo- 
controlled. multiwater study demunrtrates that clentiazem 
is safe and affective tnonothempy for stable angina. These 
results should be contkmed in a study with a longer dmatioa 
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of treatment. ll16 minimal d&be dose appfam tD be 
40 n#day. With 80 6nd JM @day, antia@md c.&acy 
aersists for 12 h. alkwin~ for a tWice daily dosina schedule. 
Fust-degree AV’block wk seen in 10% 2 pntieofa receiving 
the MI-m&iSy dose. This adverse e&t may limit the 
maxiplally recommended dox of ckntii. 
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